Borderline ovarian tumors: modern diagnostic criteria at the preoperative stage

Abstract

AIM: The aim of this study was to define and standardize the clinical and diagnostic criteria for borderline ovarian tumors at the preoperative stage.

MATERIALS AND METHODS: A retrospective analysis of 35 clinical case histories of patients with morphologically established borderline ovarian tumors has been conducted. Clinical and morphological data were analyzed: age, anamnesis, examination data, disease stage, histological study results. Laboratory parameters were assessed: CA-125 tumor marker level and ultrasound characteristics using criteria defined by IOTA, ADNEX and O-RADS groups.

RESULTS: A single cyst with a solid component was a typical ultrasound type of borderline ovarian tumors (45.71%). The application of the simple IOTA rules in regards to evaluating the formations proved possible in 100% of the cases and the formation was regarded as undefined in 62.86% of the cases. In 51.43% of the cases, the formation belonged to O-RADS 4 (10% to <50% risk of malignancy). The study of CA-125 tumor marker levels showed insufficient sensitivity, only 57.14% of patients having the parameter above the norm.

CONCLUSIONS: The application of the IOTA and O-RADS criteria allows for differentiating not only benign and malignant, but also borderline ovarian tumors, thus determining the choice of an organ-preserving treatment for patients of reproductive age.

Keywords

ovary / ovarian neoplasms / cancer antigen 125 / ultrasound diagnostics

References

[1] Gozman ES, Makarova NA. Histological, genetic, immunohistochemical markers of borderline ovarian tumors. Vestnik Volgogradskogo gosudarstvennogo medicinskogo universiteta. 2021;(3):8–14. (In Russ.). DOI: 10.19163/1994-9480-2021-3(79)-8-14

[2] Гозман Е.С., Макарова Н.А. Гистологические, генетические, иммуногистохимические маркеры пограничных опухолей яичников // Вестник Волгоградского государственного медицинского университета. 2021. № 3 (79). С. 8–14. DOI: 10.19163/1994-9480-2021-3(79)-8-14

[3] Novikova EG, Shevchuk AS. Sovremennye podkhody k lecheniyu bol’nykh s pogranichnymi opukholyami yaichnikov. Oncogynecology. 2014;(4):45–58. (In Russ.)

[4] Новикова Е.Г., Шевчук А.С. Современные подходы к лечению больных с пограничными опухолями яичников // Онкогинекология. 2014. № 4. С. 45–58.

[5] Davydova IYu, Kuznetsov VV, Karseladze AI, Meshcheryakova LA. Borderline ovarian tumors. Akusherstvo i ginekologiya. Novosti. Mneniya. Obucheniya. 2019;(7):92–104. (In Russ.). DOI: 10.24411/2303-9698-2019-11013

[6] Давыдова И.Ю., Кузнецов В.В., Карселадзе А.И., Мещерякова Л.А. Пограничные опухоли яичников // Акушерство и гинекология. Новости. Мнения. Обучения. 2019. Т. 7. № 1. С. 92–104. DOI: 10.24411/2303-9698-2019-11013

[7] Davydova IYu, Kuznetsov VV, Karseladze AI, Meshcheryakova LA. Borderline ovarian tumors: а modern view of the problem. Opukholi zhenskoy reproduktivnoy sistemy. 2014;(2):53–55. (In Russ.)

[8] Давыдова И.Ю., Кузнецов В.В., Карселадзе А.И., Мещерякова Л.А. Пограничные опухоли яичников: современный взгляд на проблему // Опухоли женской репродуктивной системы. 2014. № 2. С. 53–55.

[9] Davydova IYu, Ashrafyan LA, Karseladze AI, et al. Prakticheskie rekomendatsii po lecheniyu pogranichnykh opukholey yaichnikov. Zlokachestvennye opukholi. 2021;10(3s2–1):210–220. (In Russ.). DOI: 10.18027/2224-5057-2019-9-3s2-192-202

[10] Давыдова И.Ю., Ашрафян Л.А., Карселадзе А.И. и др. Практические рекомендации по лечению пограничных опухолей яичников // Злокачественные опухоли. 2021. Т. 10. № 3s2–1. С. 210–220. DOI: 10.18027/2224-5057-2019-9-3s2-192-202

[11] Bourdel N, Huchon C, Abdel Wahab C, et al. Borderline ovarian tumors: Guidelines from the French national college of obstetricians and gynecologists (CNGOF). Eur J Obstet Gynecol Reprod Biol. 2021;(256):492–501. DOI: 10.1016/j.ejogrb.2020.11.045

[12] Bourdel N., Huchon C., Abdel Wahab C. et al. Borderline ovarian tumors: Guidelines from the French national college of obstetricians and gynecologists (CNGOF) // Eur. J. Obstet. Gynecol. Reprod. Biol. 2021. Vol. 256. P. 492–501. DOI: 10.1016/j.ejogrb.2020.11.045

[13] Flicek KT, van Buren W, Dudiak K, et al. Borderline epithelial ovarian tumors: what the radiologist should know. Abdom Radiol (NY). 2021;(46):2350–2366. (In Russ.). DOI: 10.1007/s00261-020-02688-z

[14] Flicek K.T., van Buren W., Dudiak K. et al. Borderline epithelial ovarian tumors: what the radiologist should know // Abdom. Radiol. 2021. Vol. 46. P. 2350–2366. DOI: 10.1007/s00261-020-02688-z

[15] Tamakoshi K, Kikkawa F, Shibata K, et al. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor. Gynecol Oncol. 1996;62(1):67–72. (In Russ.). DOI: 10.1006/gyno.1996.0191

[16] Tamakoshi K., Kikkawa F., Shibata K. et al. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor // Gynecol. Oncol. 1996. Vol. 62. No. 1. P. 67–72. DOI: 10.1006/gyno.1996.0191

[17] Vasil’ev AN, Krasil’nikov SE, Voytsitskiy VE, et al. Onkomarkery SA 125, NE 4 kak prediktornye faktory prognoza u bol’nykh s pogranichnymi opukholyami yaichnikov. Sibirskiy onkologicheskiy zhurnal. 2015;(4):39–44. (In Russ.)

[18] Васильев А.Н., Красильников С.Э., Войцицкий В.Е. и др. Онкомаркеры СА 125, НЕ 4 как предикторные факторы прогноза у больных с пограничными опухолями яичников // Сибирский онкологический журнал. 2015. № 4. С. 39–44.

[19] Timmerman D, van Calster B, Testa AC, et al. Ovarian cancer prediction in adnexal masses using ultrasound-based logistic regression models: a temporal and external validation study by the IOTA group. Ultrasound Obstet Gynecol. 2010;(36):226–234.

[20] Timmerman D., van Calster B., Testa A.C. et al. Ovarian cancer prediction in adnexal masses using ultrasound-based logistic regression models: a temporal and external validation study by the IOTA group // Ultrasound Obstet. Gynecol. 2010. Vol. 36. P. 226–234.

[21] Garg S, Kaur A, Mohi JK, et al. Evaluation of IOTA simple ultrasound rules to distinguish benign and malignant ovarian tumours. J Clin Diagn Res. 2017;11(8):TC06–TC09. DOI: 10.7860/JCDR/2017/26790.10353

[22] Garg S., Kaur A., Mohi J.K. et al. Evaluation of IOTA simple ultrasound rules to distinguish benign and malignant ovarian tumours // J. Clin. Diagn. Res. 2017. Vol. 11. No. 8. P. TC06–TC09. DOI: 10.7860/JCDR/2017/26790.10353

[23] Kaijser J, Sayasneh A, van Hoorde K, et al. Presurgical diagnosis of adnexal tumours using mathematical models and scoring systems: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(3):449–462. DOI: 10.1093/humupd/dmt059

[24] Kaijser J., Sayasneh A., van Hoorde K. et al. Presurgical diagnosis of adnexal tumours using mathematical models and scoring systems: a systematic review and meta-analysis // Hum. Reprod. Update. 2014. Vol. 20. No. 3. P. 449–462. DOI: 10.1093/humupd/dmt059

[25] Adamyan LV, Andreeva EN, Artymuk NV, et al. Diagnostika i lechenie dobrokachestvennykh novoobrazovaniy yaichnikov s pozitsii profilaktiki raka. Klinicheskie rekomendatsii. Problemy reproduktsii. 2018;24(S6) 827–855. (In Russ.)

[26] Адамян Л.В., Андреева Е.Н., Артымук Н.В. и др. Диагностика и лечение доброкачественных новообразований яичников с позиции профилактики рака. Клинические рекомендации // Проблемы репродукции. 2018. Т. 24. № S6. С. 827–855.

[27] Van Calster B, Van Hoorde K, Valentin L, et al. Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study. BMJ. 2014;349:g5920. DOI: 10.1136/bmj.g5920

[28] Van Calster B., van Hoorde K., Valentin L. et al. Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study // BMJ. 2014. Vol. 349. P. g5920. DOI: 10.1136/bmj.g5920

[29] Andreotti RF, Timmerman D, Strachowski LM, et al. O-RADS US risk stratification and management system: A consensus guideline from the ACR ovarian-adnexal reporting and data system committee. Radiology. 2020;294(1):168–185. (In Russ.). DOI: 10.1148/radiol.2019191150

[30] Andreotti R.F., Timmerman D., Strachowski L.M. et al. O-RADS US risk stratification and management system: A consensus guideline from the ACR ovarian-adnexal reporting and data system committee // Radiology. 2020. Vol. 294. No. 1. P. 168–185. DOI: 10.1148/radiol.2019191150

RIGHTS & PERMISSIONS

Eсо-Vector